Spyre Therapeutics SYRE
NASDAQ SYRE
$104.80 -2.02 (-1.89%)
As of: Nov 12, 2026 · 9:30 AM EST

Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2015 - 2026)

Updated

Analysis

Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2015 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Spyre Therapeutics 9.40 Bn 5.68 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Mar 31, 2026 30.00 Mn
Jun 30, 2025 10.00 Mn
Dec 31, 2023 1.84 Mn
Sep 30, 2023 14.61 Mn
Mar 31, 2015 -2,000.00
API Access

Spyre Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SYRE&period=max&api_key=YOUR_API_KEY